Guerbet is a pharmaceutical group specialized in medical imaging providing contrast media for diagnostic purposes. The company’s origin is linked to Marcel Guerbet’s discovery of the first organic iodinated contrast medium in 1901, Lipiodol®.
The Guerbet company was created in 1926 by André Guerbet. Since then, the company’s significant growth has been driven by regular innovations in medical imaging technologies accompanied by the introduction of new contrast media.
Over the last 40 years, Guerbet’s own research and development resulted in the launching of four major products: Telebrix®, Hexabrix®, Dotarem® and Xenetix®
And Guerbet successfully launch CT injector, Flowsens®